Understanding factors that shape the immune landscape across hematological malignancies is essential for immunotherapy development. We integrated over......
Dufva, O; Polonen, P; Bruck, O; Keranen, MA; Klievink, J; Mehtonen, J; Huuhtanen, J; Kumar, A; Malani, D; Siitonen, S; Kankainen, M; Ghimire, B; Lahtela, J; Mattila, P; Vaha-Koskela, M; Wennerberg, K; Granberg, K; Leivonen, SK; Meriranta, L; Heckman, C; Leppa, S; Nykter, M; Lohi, O; Heinaniemi, M; Mustjoki, S
Mustjoki, S (corresponding author), Univ Helsinki, Hosp Comprehens Canc Ctr HUH CCC, Hematol Res Unit Helsinki, Helsinki 00029, Finland.; Mustjoki, S (corresponding author), Univ Helsinki UH, Translat Immunol Res Program, Helsinki 00029, Finland.; Mustjoki, S (corresponding author), Univ Helsinki UH, Dept Clin Chem & Hematol, Helsinki 00029, Finland.; Mustjoki, S (corresponding author), iCAN Digital Precis Canc Med Flagship, Helsinki, Finland.; Heinaniemi, M (corresponding author), Univ Eastern Finland, Sch Med, Inst Biomed, Kuopio 70211, Finland.
CANCER CELL, 2020; 38 (3): 380